Major Depressive Disorder

What is new in research on major depressive disorder?

Eric Nestler, MD, PhD, reflects on his research and new role as dean of the Icahn School of Medicine.

Explore how lifestyle psychiatry transforms depression treatment through nutrition, exercise, sleep, and social connections for holistic recovery and resilience.

Seltorexant shows promise as a safe adjunctive treatment for patients with major depressive disorder and insomnia symptoms, with fewer weight changes than quetiapine XR.

New data reveals Caplyta significantly improves remission rates in adults with major depressive disorder, offering hope for lasting relief from symptoms.

Innovative combinations of transcranial magnetic stimulation and ketamine therapy offer new hope for treatment-resistant depression, pain, and substance use disorders.

FDA approves ProlivRx, a groundbreaking at-home therapy for major depressive disorder, offering new hope for patients unresponsive to traditional treatments.

Biohaven's BHV-7000 fails to reduce depressive symptoms in a phase 2 proof-of-concept study.

A groundbreaking at-home brain stimulation device gains FDA approval, offering hope for adults with major depressive disorder through innovative treatment.

What is the neuroplasticity hypothesis and why is it more important now than ever?

Explore updates from November 2025, including AI, drug updates, and more.

Explore the transformative role of TMS in treating depression, its innovative protocols, and future advancements in psychiatric care.

How can the glutamate model overcome challenges in treating major depressive disorder?

Vagus nerve stimulation offers a promising solution for treatment-resistant depression, showcasing significant long-term efficacy and durability in patients.

What novel treatments can be game changers for major depressive disorder?

FDA expands Deep TMS therapy for adolescents with major depressive disorder, offering a noninvasive treatment option for underserved youth.

EXCLUSIVE: Check out this recap on the approval of lumateperone (Caplyta) for major depressive disorder.

Explore how placebo effects vary across psychiatric disorders, revealing significant symptom improvements, especially in major depressive disorder and generalized anxiety disorder.

Caplyta, now FDA-approved as an adjunctive therapy for major depressive disorder, offers rapid relief and a favorable safety profile for patients. Learn more from Suresh Durgam, MD, the primary investigator.

Neurocrine's NBI-1070770 fails to meet primary endpoint in phase 2 trial for major depressive disorder, prompting further analysis of results.

AtaiBeckley reveals promising phase 2b open-label extension study results for BPL-003, showing sustained antidepressant effects in patients with treatment-resistant depression after redosing.

Roger S. McIntyre, MD, FRCPC, shares how FDA approval of Caplyta will benefit patients with major depressive disorder

Johnson & Johnson's Caplyta gains FDA approval as an adjunctive treatment for major depressive disorder, offering hope for improved patient outcomes.